Elastomeric leaflet for prosthetic heart valves

Information

  • Patent Grant
  • 10993803
  • Patent Number
    10,993,803
  • Date Filed
    Thursday, July 27, 2017
    7 years ago
  • Date Issued
    Tuesday, May 4, 2021
    3 years ago
Abstract
A leaflet for a prosthetic valve formed of at least one layer that includes a composite material containing at least one expanded fluoropolymer membrane having serpentine fibrils and an elastomer is provided. The fluoropolymer may be polytetrafluoroethylene. In at least one embodiment, the elastic properties are present in an axial direction the leaflet. The leaflets may be single layered or multi-layered. The leaflets may be coupled to a support structure and movable between open and closed configurations relative to the support structure to form a heart valve. The elasticity within the leaflets permits, among other things, the leaflets to bend with a reduced occurrence of wrinkles as the valve opens and closes. The elastic properties of the leaflet also, among other things, improve bending properties and reduce closure stresses, thereby extending the life of the leaflet.
Description
FIELD

The subject matter disclosed herein relates to materials used in medical implants, and more particularly, to a leaflet that includes at least one layer of a composite material that includes an expanded polytetrafluoroethylene (ePTFE) membrane containing serpentine fibrils and an elastomer. The elastomer may be located in all or substantially all of the pores of the ePTFE membrane.


BACKGROUND

Artificial heart valves desirably last at least ten years in vivo. To last that long, artificial heart valves should exhibit sufficient durability for at least four hundred million cycles or more. The valves, and more specifically heart valve leaflets, must resist structural degradation including the formation of holes, tears, and the like as well as adverse biological consequences such as calcification and thrombosis.


Fluoropolymers, such as expanded and non-expanded forms of polytetrafluoroethylene (PTFE), modified PTFE, and copolymers of PTFE, offer a number of desirable properties, including excellent inertness and superior biocompatibility, and therefore make ideal candidate materials for artificial heart valves. Additionally, PTFE and expanded PTFE (ePTFE) have been used to create heart valve leaflets. It has been shown, however, that PTFE stiffens with repeated flexure, which can lead to unacceptable flow performance. Failure due to formation of holes and tears in the material has also been observed. A variety of polymeric materials has previously been employed as prosthetic heart valve leaflets. Failure of these polymeric leaflets due to stiffening and hole formation typically occurred within two years of implant. Efforts to improve leaflet durability by thickening the leaflets resulted in unacceptable hemodynamic performance of the valves, that is, the pressure drop across the open valve was too high. Conventional leaflets also experience wrinkling, which can be sites of potential failure of the heart valve.


Thus, there remains a need in the art for a biocompatible artificial heart valve, including leaflets, that is durable and reduces the occurrence of wrinkles during the cycling of the heart valve between open and closed configurations.


SUMMARY

According to an embodiment, a prosthetic valve is provided for regulating blood flow direction in a human patient. Such a prosthetic valve includes, but is not limited to, a cardiac valve or a venous valve.


Embodiments provided herein utilize fluoropolymer membranes that exhibit significant elongation while substantially retaining the strength properties of the fluoropolymer membrane. Such fluoropolymer membranes characteristically possess serpentine fibrils.


Other embodiments provide a prosthetic valve for regulating blood flow direction within a patient that includes a leaflet having at least one layer of a composite material that contains at least one expanded fluoropolymer membrane having serpentine fibrils and an elastomer. In embodiments, the elastomer is present in all or substantially all of the pores of the fluoropolymer membrane. The fluoropolymer membrane may have a microstructure of substantially only serpentine fibrils. In some embodiments, the expanded fluoropolymer membrane includes a plurality of serpentine fibrils. In addition, the fluoropolymer may be polytetrafluoroethylene. The leaflet may be formed of a single layer or multiple layers of the composite material. Additionally, the leaflets may be operatively connected to a support structure and movable between open and closed configurations relative to the support structure to form a heart valve. The elasticity within the leaflets permits the leaflets to bend with a reduced occurrence of wrinkling as the valve opens and closes. Leaflets formed of the composite material exhibit no visible signs of holes, tears, or delamination and remain otherwise unchanged after actuation of the leaflet for at least 100 million cycles.


Other embodiments provide an implantable prosthetic valve for regulating blood flow direction in a patient that includes a leaflet cyclable between a closed configuration to substantially prevent blood flow through the prosthetic valve and an open configuration to allow blood flow through the prosthetic valve. The leaflet is formed of at least one layer of a composite material that includes at least one expanded fluoropolymer membrane having serpentine fibrils and an elastomer. The elastomer is present in all or substantially all of the pores of the expanded fluoropolymer membrane. In addition, the expanded fluoropolymer membrane may include a microstructure of substantially only serpentine fibrils. The expanded fluoropolymer membrane may include a plurality of serpentine fibrils. In some embodiments, the fluoropolymer is polytetrafluoroethylene. The leaflet has a reduced occurrence of wrinkling in the open and closed configurations of the prosthetic valve. Additionally, the leaflet may be may be coupled to a rigid or an elastic support structure in a conventional manner to form a heart valve.


Embodiments provided herein provide a method of forming a leaflet of an implantable prosthetic valve for regulating blood flow direction in a patient that includes providing a composite material that includes at least one expanded fluoropolymer membrane having serpentine fibrils and an elastomer and bringing at least one layer of the composite material into contact with additional layers of the composite material by wrapping a sheet of the composite material with a starting and ending point defined as an axial seam adhered to itself. The elastomer may be present in all or substantially all of the pores of the expanded fluoropolymer membrane. In accordance with an embodiment, the elastic properties of the leaflet are present in the axial direction of the leaflet. The fluoropolymer may be polytetrafluoroethylene. Also, the expanded fluoropolymer membrane may include a microstructure of substantially only serpentine fibrils. In accordance with another embodiment, the expanded fluoropolymer membrane includes a plurality of serpentine fibrils.


Other embodiments provide an implantable prosthetic valve for regulating blood flow direction in a patient that includes a support structure and a leaflet formed of at least one layer that includes a composite material containing at least one expanded fluoropolymer membrane having serpentine fibrils and an elastomer. The expanded fluoropolymer membrane includes a plurality of pores and the elastomer is present in all or substantially all of the pores. Additionally, the leaflet is movable relative to the support structure and is cyclable between a closed configuration and an open configuration. The leaflet has a reduced occurrence of wrinkling in both the open and closed configurations. In some embodiments, the fluoropolymer is polytetrafluoroethylene. The expanded fluoropolymer membrane may include a microstructure of substantially only serpentine fibrils. The expanded fluoropolymer membrane may include a plurality of serpentine fibrils.


Other embodiments provide an prosthetic valve that includes a leaflet having at least one layer comprising a composite material that exhibits an increase in stiffness when elongated to at least about 30% strain. The composite material includes at least one expanded fluoropolymer membrane and an elastomer. The expanded fluoropolymer membrane may include serpentine fibrils. Also, the expanded fluoropolymer membrane may include a plurality of serpentine fibrils. In an embodiment, the expanded fluoropolymer membrane includes a plurality of pores and the elastomer is present in substantially all of the pores.


An embodiment of a method of forming a leaflet includes providing a composite material that exhibits an increase in stiffness when elongated to at least about 30% strain and bringing at least one layer of the composite material into contact with additional layers of the composite material by wrapping a sheet of the composite material with a starting and ending point defined as an axial seam adhered to itself. The composite material includes at least one expanded fluoropolymer membrane and an elastomer, and, in some embodiments, may include serpentine fibrils.


Leaflets formed with the composite material may be operatively coupled to a support structure and movable between closed and open configurations relative to the support structure to form a heart valve.


Leaflets in accordance with embodiments provided herein demonstrate a reduction of wrinkling as the heart valves cycle between an open configuration and a closed configuration.


Embodiments provided herein provide that the elastomer may be present in all or substantially all of the pores of the fluoropolymer membrane.


Other embodiments provide that additional materials may be incorporated into the pores of the expanded fluoropolymer membrane or between the layers of the composite material forming the leaflet to enhance desired properties of the leaflet.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 is a schematic illustration of an exemplary, idealized serpentine fibril, in accordance with an embodiment;



FIG. 2 is a scanning electron micrograph (SEM) of the surface of a leaflet with the fluoroelastomer removed taken at 10000×, in accordance with an embodiment;



FIG. 3A is a graphical illustration showing the unrecoverable strain energy density of a sample, in accordance with an embodiment;



FIG. 3B is a graphical illustration showing the recoverable strain energy density of the sample of FIG. 3A;



FIG. 3C is a graphical illustration showing the total strain energy density of the sample of FIG. 3A;



FIG. 4 is graphical illustration of the percent unrecoverable strain energy density of the sample made in accordance with Example 1, in accordance with an embodiment;



FIG. 5 is a graphical illustration of stress versus strain of a composite in the direction orthogonal to the strongest direction according to an embodiment where the intersection of tangent lines depicts a stop point of the composite, in accordance with an embodiment;



FIG. 6 is a schematic illustration of a cylindrically-shaped cut support structure, in accordance with an embodiment;



FIG. 7 is a schematic illustration of a mandrel having a generally cylindrical shape shown, in accordance with an embodiment;



FIG. 8 is a schematic illustration of depicting the position of the support structure on the mandrel, in accordance with an embodiment; and



FIGS. 9A and 9B are top views of a valve in the closed and open position, respectively, in accordance with an embodiment.





DETAILED DESCRIPTION OF THE INVENTION

References will now be made to embodiments illustrated in the drawings and specific language which will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications in the illustrated methods and apparatus, as such further applications of the principles of the invention as illustrated therein as being contemplated as would normally occur to one skilled in the art to which the invention relates.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. In the drawings, the thickness of the lines, layers, and regions may be exaggerated for clarity. Like numbers found throughout the figures denote like elements.


As used herein, the term “serpentine fibrils” means multiple fibrils that curve or turn one way then another.


As used herein, the term “controlled retraction” refers to causing articles to shorten in length in at least one direction by the application of heat, by wetting with a solvent, or by any other suitable means or combinations thereof in such a way as to inhibit folding, pleating, or wrinkling of the subsequent article visible to the naked eye.


The term “wrinkling” also refers to the appearance of the composite material upon bending or flexing of the otherwise wrinkle-free composite material forming the leaflet.


As used herein, the term “wrinkle-free” is meant to denote that the composite material is free of wrinkles prior to bending or flexing the composite material.


The term “imbibed or imbibing” as used herein is meant to describe any means for at least partially filling at least a portion of the pores of a porous material such as ePTFE or the like.


The term “elongation” or “elongated” as used herein is meant to denote the increase in length in response to the application of a force.


The term “leaflet” as used herein is meant to denote a component of a prosthetic valve for regulating blood flow direction. Leaflets according to the present embodiments are formed of one or more layers of a composite material including an expanded fluoropolymer membrane having serpentine fibrils and an elastomer.


The term “elastic” as used herein refers to the property of a material to be elongated upon the application of a force and that returns to its approximate original dimensions upon the release of the force due to the retraction force of the material.


The term “increase in stiffness” as used herein refers the increase in resistance to further elongation once the stop-point is reached.


The terms “node” and “fibril” as used herein refers to particular characteristic shapes of elements of the structure of an expanded fluoropolymer membrane, as is known in the art of expanded fluoropolymer membranes.


In one embodiment, fluoropolymer membranes that exhibit high elongation while substantially retaining the strength properties of the fluoropolymer membrane are utilized. Such membranes characteristically possess serpentine fibrils, such as the idealized serpentine fibril exemplified in FIG. 1. As depicted generally in FIG. 1, a serpentine fibril curves or turns generally one way in the direction of first arrow 10 then generally another way in the direction of second arrow 20. It is to be understood that the amplitude, frequency, or periodicity of the serpentine-like fibrils as exemplified in FIG. 1 may vary. In one embodiment, the fluoropolymer membranes are expanded fluoropolymer membranes. Non-limiting examples of expandable fluoropolymers include, but are not limited to, expanded PTFE, expanded modified PTFE, and expanded copolymers of PTFE. Patents have been filed on expandable blends of PTFE, expandable modified PTFE, and expanded copolymers of PTFE, such as, for example, U.S. Pat. No. 5,708,044 to Branca; U.S. Pat. No. 6,541,589 to Baillie; U.S. Pat. No. 7,531,611 to Sabol et al.; U.S. patent application Ser. No. 11/906,877 to Ford; and U.S. patent application Ser. No. 12/410,050 to Xu et al.


The high elongation is enabled by forming relatively straight fibrils into serpentine fibrils that substantially straighten upon the application of a force in a direction opposite to the compressed direction. The creation of the serpentine fibrils can be achieved through a thermally-induced controlled retraction of the expanded polytetrafluoroethylene (ePTFE), through wetting the article with a solvent, such as, but not limited to, isopropyl alcohol or Fluorinert® (a perfluorinated solvent commercially available from 3M, Inc., St. Paul, Minn.), or by a combination of these two techniques. The retraction of the article does not result in visible pleating, folding, or wrinkling of the ePTFE, unlike what occurs during mechanical compression. The retraction also can be applied to very thin membranes, unlike known methods. During the retraction process, the fibrils not only become serpentine in shape but also may also increase in width.


The precursor materials can be biaxially expanded ePTFE membranes. In one embodiment, materials such as those made in accordance with the general teachings of U.S. Pat. No. 7,306,729 to Bacino, et al. are suitable precursor membranes, especially if small pore size articles are desired. These membranes may possess a microstructure of substantially only fibrils. The precursor membrane may or may not be amorphously locked. The precursor membrane may also be at least partially filled, coated, imbibed, or otherwise combined with additional materials (e.g., elastomeric materials).


The precursor membrane may be restrained in one or more directions during the retraction process in order to prescribe the desired amount of elongation of the final article. The amount of elongation is directly related to, and determined by, the amount of retraction.


In one embodiment, retraction can be achieved in a uniaxial tenter frame by positioning the rails at a distance less than the width of the precursor membrane prior to the application of heat or solvent or both. When using a biaxial tenter frame, one or both of the sets of grips, pins, or other suitable attachment means can similarly be positioned at a distance less than the dimensions of the precursor membrane. It is to be appreciated that these retraction means differ from the mechanical compression taught by the House and Sowinski patents noted above. Upon retraction, the expanded fluoropolymer membrane possesses serpentine fibrils. These retracted membranes characteristically possess serpentine fibrils and are substantially wrinkle free. In some exemplary embodiments, the retracted membranes may possess a microstructure of substantially only serpentine fibrils. In at least one embodiment, the fluoropolymer membranes include a plurality of serpentine fibrils. As used herein, the phrase “plurality of serpentine fibrils” is meant to denote the presence of 2 or more, 5 or more, 10 or more, or 15 or more serpentine fibrils in the fluoropolymer membrane within a field of view as taught below.


At least one elastomeric material can be added to the precursor membrane prior, during, or subsequent to retraction to form a composite. In the absence of such elastomeric materials, fluoropolymer articles having serpentine fibrils do not exhibit appreciable recovery after elongation. Suitable elastomeric materials may include, but are not limited to, PMVE-TFE (perfluoromethylvinyl ether-tetrafluoroethylene) copolymers, PAVE-TFE (perfluoro (alkyl vinyl ether)-tetrafluoroethylene) copolymers, silicones, polyurethanes, and the like. It is to be noted that PMVE-TFE and PAVE-TFE are fluoroelastomers. Other fluoroelastomers are suitable elastomeric materials. The resultant retracted article not only possesses high elongation while substantially retaining the strength properties of the fluoropolymer membrane, it also possesses an additional property of low percent unrecoverable strain energy density. These retracted articles can exhibit percent unrecoverable strain energy density values less than about 90%, less than about 85%, less than about 80%, less than about 70%, less than about 60%, and lower, including any and all percentages therebetween.


In one embodiment, a composite material including an expanded fluoropolymer membrane having serpentine fibrils and an elastomer as described above forms the leaflet materials of a heart valve. The composite material is substantially free of wrinkles. It is to be appreciated that the use of a single layer or multiple layers of the expanded fluoropolymer membrane and multiple types of elastomeric materials are considered to be within the scope of the present disclosure. Additional materials may also be incorporated into the pores of the expanded fluoropolymer membrane and/or between layers of the composite material forming the leaflet to enhance desired properties of the leaflet. The fluoropolymer membrane exhibits significant elongation while substantially retaining the strength properties of the fluoropolymer membrane.


The composite material provides performance attributes required for use in high-cycle flexural implant applications, such as heart valve leaflets, in several significant ways. For example, the inclusion of the elastomer improves the fatigue performance of the leaflet by eliminating or reducing stiffening that is typically observed with ePTFE-only materials. In addition, the incorporation of an elastomer reduces the likelihood that the material will undergo permanent set deformation, such as wrinkling or creasing, that could result in compromised performance.


Composite materials of embodiments herein not only exhibit elongation, but also exhibit a dramatic increase in stiffness after achieving a high, optionally predetermined, elongation. As a consequence, the composite materials can be elongated to a point at which further elongation is inhibited by the dramatic increase in stiffness. The composite material has a stop point at which further elongation occurs only in conjunction with a significant increase in pressure or force. The composite material exhibits an increase in stiffness when elongated to at least about 30% strain, to at least about 35% strain, to at least about 40% strain, to at least about 45% strain, to at least about 50% strain, to at least about 55% strain, and even greater.


As discussed above, the elastomer may be combined with the expanded fluoropolymer membrane such that the elastomer occupies all or substantially all of the pores within the expanded fluoropolymer membrane. The term “substantially all of the pores” as used herein is meant to denote that the elastomer is present in at least a portion of all or nearly all of the pores of the expanded fluoropolymer (ePTFE) membrane. Having elastomer present in all or substantially all of the pores of the fluoropolymer membrane reduces the space in which foreign materials can be undesirably incorporated into the composite material. An example of such a foreign material is calcium. For instance, if calcium becomes incorporated into the composite material used in a heart valve leaflet, mechanical damage can occur during cycling, which can lead to the formation of holes in the leaflet and degradation in hemodynamics. On the other hand, the incorporation of additional, desired materials into the pores of the expanded fluoropolymer membrane and/or between layers of the composite material forming the leaflet can enhance desired properties of the leaflet, and are considered to be within the scope of the invention.


Leaflets constructed from the composite material can be assembled in a variety of configurations based on desired laminate or leaflet thickness and number of layers of composite material. Leaflets according to some embodiments may be composed of a single layer of the composite material or multiple layers of the composite material. Multi-layers provide for enhanced durability and increased damage reduction to the leaflet. The maximum number of layers within the leaflet is determined, at least in part, by the desired thickness of the leaflet. The leaflet has a ratio of thickness (μm) to number of layers of composite material of less than about 5. In addition, the leaflets may be affixed to a rigid or an elastic frame in a conventional manner, such as, for example, to form a heart valve.


The elasticity within the leaflet greatly reduces the occurrence of wrinkles as the heart valves cycle between an open configuration and a closed configuration. The elastic properties of the leaflet may be present in the axial direction of the leaflet. By “axial direction of the leaflet”, it is meant that the direction from the base of the leaflet to the free edge of the leaflet. In addition, the leaflets may have elastic properties in other, non-axial, direction(s). Thus, leaflets formed with the inventive composite material demonstrate a reduction in wrinkling as they bend and flex with the opening and closing of a heart valve. In addition, the elasticity of the leaflet slows accelerations and reduces the forces imposed on the leaflet, thereby extending the life of the leaflet. Leaflets formed of the composite material exhibit no visible signs of holes, tears, or delamination and have unchanged performance after actuation of the leaflet to at least 100 million cycles, and even to at least 200 million cycles.


Additionally, the elastic properties of the leaflet improve bending properties and reduce closure stresses. Bending properties generally refer to the qualitative amount of wrinkles and/or creases developed with in the leaflet structure during deformations induced by cyclic opening and closing.


Having generally described various embodiments, a further understanding can be obtained by reference to certain specific examples illustrated below which are provided for purposes of illustration only and are not intended to be all inclusive or limiting unless otherwise specified.


Testing Methods

It should be understood that although certain methods and equipment are described below, any method or equipment determined suitable by one of ordinary skill in the art may be alternatively utilized.


Mass, Thickness, and Density

Membrane samples were die cut to form rectangular sections about 2.54 cm by about 15.24 cm to measure the weight (using a Mettler-Toledo analytical balance model AG204) and thickness (using a Käfer Fz1000/30 snap gauge). Using these data, density was calculated with the following formula: ρ=m/(w*l*t), in which: ρ=density (g/cm3), m=mass (g), w=width (cm), l=length (cm), and t=thickness (cm). The average of three measurements was reported.


Matrix Tensile Strength (MTS) of Membranes

Tensile break load was measured using an INSTRON 122 tensile test machine equipped with flat-faced grips and a 0.445 kN load cell. The gauge length was about 5.08 cm and the cross-head speed was about 50.8 cm/min. The sample dimensions were about 2.54 cm by about 15.24 cm. For highest strength measurements, the longer dimension of the sample was oriented in the highest strength direction. For the orthogonal MTS measurements, the larger dimension of the sample was oriented perpendicular to the highest strength direction. Each sample was weighed using a Mettler Toledo Scale Model AG204, then the thickness was measured using the Käfer FZ1000/30 snap gauge; alternatively, any suitable means for measuring thickness may be used. The samples were then tested individually on the tensile tester. Three different sections of each sample were measured. The average of the three maximum loads (i.e., peak force) measurements was reported. The longitudinal and transverse matrix tensile strengths (MTS) were calculated using the following equation: MTS=(maximum load/cross-section area)*(bulk density of PTFE)/(density of the porous membrane), where the bulk density of the PTFE was taken to be about 2.2 g/cm3.


Tensile Strength of Composites

Composite tensile testing was performed using an RSA3 dynamic mechanical analyzer (TA Instruments, New Castle, Del.) with a 3500 g load cell. 13 mm×39 mm rectangular samples were mounted with a 20 mm gauge length and strained at a rate of 1000%/minute. For highest strength measurements, the longer dimension of the sample was oriented in the highest strength direction. For the orthogonal tensile strength measurements, the larger dimension of the sample was oriented perpendicular to the highest strength direction. Reported data are an average of at least 3 measurements.


Elongation Testing

Elongation of the retracted article can be measured by any suitable application of tensile force, such as, for example, by the use of a tensile testing machine, by hand, or by applying internal pressure to a tubular article. In the embodiments presented herein, elongation was performed at a rate of about 10% per second in all directions that were elongated. Elongation was calculated as the final length minus the initial length, divided by the initial length, and was reported as a percentage. The average of three measurements was reported.


Percent Unrecoverable Strain Energy Density

The percent unrecoverable strain energy density of composites was measured using an RSA3 dynamic mechanical analyzer (TA Instruments, New Castle, Del.) with a 3500 g load cell. A 13 mm×39 mm rectangular sample was cut so that the longer dimension was oriented in the highest strength direction. The sample was mounted in film/fiber tension grips with a 20 mm gauge length. The grips were programmed to elongate the sample to 50% strain at a rate of 200 mm/minute and were then immediately returned to the initial displacement at a rate of 200 mm/minute. Load and displacement values were collected, converted to stress and strain values, and then graphed. The unrecoverable strain energy density is represented by the first area 101 between the elongation and return curve as depicted in FIG. 3A, shown as hatching. The recoverable strain energy density is represented by the second area 102 in FIG. 3B, shown as hatching.


The percent unrecoverable strain energy density of the sample is defined by the first area 101 between the elongation and return curve as shown in FIG. 3A, divided by the third area 103 under the elongation curve from 0% to 50% strain as shown in FIG. 3C, shown as crosshatching, then multiplied by 100%. Reported data are an average of at least three measurements.


Should the sample break prior to 50% strain, then another sample should be tested at 50% of the breakage strain to calculate the unrecoverable strain energy density. For samples that are too small to accommodate the 20 mm grip separation and allow enough material within the grips to prevent slippage of the sample within the grips, other combinations of crosshead speed and grip separation may be used provided the ratio of crosshead speed to initial grip separation is equal to 10 minutes.


Scanning Electron Microscopy

Scanning electron micrographs were created choosing magnifications suitable for identifying fibrils. Articles that have been retracted in accordance with the teachings herein may require elongation in the direction of retraction in order to identify the serpentine fibrils. For the purposes of identifying the number of serpentine fibrils, a field of view of 7 microns by 7 microns of the sample is to be employed.


Removal of Elastomer

For porous fluoropolymer leaflets having pores substantially filled with elastomer, the elastomer can be dissolved or degraded and rinsed away using an appropriate solvent in order to measure or examine desired properties.


For instance, the fluoroelastomer component of a leaflet as described in Example 1 can be partially or substantially removed to enable SEM imaging of the ePTFE structure. The sample is restrained from shrinking and submerged in 95 g of Fluorinert Electronic Liquid FC-72 (3M Inc., St. Paul, Minn.) and allowed to soak without agitation. After approximately one hour, the fluorinated solvent is poured off and replaced with 95 g of fresh solvent. This process is repeated for a total of 5 soaking cycles, the first 4 cycles for approximately 1 hour, and the 5th cycle for approximately 24 hours.


To aid in the removal of elastomer, the sample can also be agitated using an ultrasonic cleaner (e.g. Branson 200 Ultrasonic Cleaner (Model—B200)).


Example

A heart valve having polymeric leaflets was formed from a composite material having an expanded fluoropolymer membrane and an elastomeric material as described above; joined to a metallic balloon expandable support structure; and was constructed according to the following process. FIGS. 9A and 9B are top views of a valve 800 in the closed and open position, respectively, in accordance with an embodiment. The valve 800 comprises a support structure 1001 and three leaflets 802 coupled to the support structure 1001.


A support structure 1001, in the form of a metallic balloon expandable structure, was laser machined from a length of 316LVM stainless steel annealed tube with an outside diameter of 25.4 mm and a wall thickness of 0.502 mm. A pattern was cut into the tube to form a cylindrically-shaped cut stent frame, also referred to as the support structure 1001, as illustrated in the flat plane view of FIG. 6. The support structure 1001 included a plurality of small closed cells 1002, a plurality of large closed cells 1003, and a plurality of leaflet closed cells 1004. It is to be noted that one of the plurality of leaflet closed cells 1004 appears as an open cell in FIG. 6 due to the flat plane view. The small closed cells 1002, large closed cells 1003, and leaflet closed cells 1004 are generally arranged along rows forming the annular shape of the support structure 1001. The support structure 1001 had 6 struts 1005, a portion of which approximates a parabolic shape, as is shown in FIG. 6.


Next, the support structure 1001 was electro-polished, which resulted in 0.025 mm material removal from each surface and left the edges rounded. The corners of support structure 1001 that would be in contact with the leaflet material were rounded using a rotary sander. The support structure 1001 was exposed to a surface roughening step to improve the adherence of leaflets to the support structure 1001, without degrading fatigue durability performance. The support structure 1001 was rinsed with water and then subjected to a plasma cleaning treatment using methods commonly known to those of ordinary skill in the art. The support structure 1001 was dipped into a 4% solution of a fluoroelastomer in PF5080, 3M, St. Paul, Minn., USA and allowed to air dry. The fluoroelastomer was formulated according to the general teachings described in U.S. Pat. No. 7,462,675 to Chang, et al. Additional fluoroelastomers may be suitable and are described in U.S. Publication No. 2004/0024448 to Chang, et al.


The fluoroelastomer consists essentially of between about 65 and 70 weight percent perfluoromethyl vinyl ether and complementally about 35 and 30 weight percent tetrafluoroethylene.


A composite material was then prepared having a membrane layer of biaxially expanded ePTFE imbibed with a fluoroelastomer. More specifically, the membrane layer of ePTFE was manufactured according to the general teachings described in U.S. Pat. No. 7,306,729. The ePTFE membrane was tested in accordance with the methods described previously. The biaxially expanded ePTFE membrane that was not amorphously locked, and had the following properties was used: thickness=0.0025 mm, density=0.236 g/cc, matrix tensile strength in the strongest direction=386 MPa, matrix tensile strength in the direction orthogonal to the strongest direction=218 MPa, elongation at maximum load in the strongest direction=24%, and elongation at maximum load in the direction orthogonal to the strongest direction=38.1%. The percent weight of the fluoroelastomer within the composite material was about 74%.


This membrane was imbibed with the fluoroelastomer described previously in this example. The fluoroelastomer was dissolved in PF5080 (3M, St Paul, Minn.) in an about 4% concentration. The solution was coated using a mayer bar onto the ePTFE membrane (while being supported by a polyethylene release film) and dried in a convection oven


A 20 mm wide strip of the composite material was rolled into a fiber and spirally wrapped around each stent frame post 1006 on the support structure 1001 of FIG. 6. This spirally wrapped composite fiber creates a cushion member which will be located between a portion of the support structure and the leaflet to minimize stress related to direct contact between the support structure and the leaflet.


A mandrel 1101 was machined from aluminum in a generally cylindrical shape shown as in FIG. 7. The mandrel 1101 contained a first end 1102 and an opposing, second end 1103. The mandrel 1101 had an outer surface 1104 having several irregular shallow pockets 1105, each generally for forming the coaptation surfaces (not shown) of a finished valve assembly (not shown).


The mandrel 1101 had forty-eight 0.5 mm diameter vent holes in the form of pocket vent holes 1107 and surface vent holes 1108. Twelve pocket vent holes 1107 were positioned at the bottom of each of the irregular shallow pockets 1105 that pass from the irregular shallow pockets 1105 to a central cavity 1106 running within the center of the mandrel 1101. Thirty-six surface vent holes 1108 were distributed across the outer surface 1104 of the mandrel 1101 that pass from the outer surface 1104 to the central cavity 1106. In a subsequent step, these pocket vent holes 1107 and surface vent holes 1108 allow for trapped air to be vented away from a valve during a molding process.


An elastomeric composite of ePTFE membrane and a fluoroelastomer was made as described hereafter. The fluoroelastomer previously described in this example was dissolved in a fluorinated solvent (Fluorinert® Electronic Liquid FC-72, 3M Inc., St. Paul, Minn.) in a ratio of 3 parts copolymer to 97 parts solvent by weight. A continuous slot die coating process operating at a line speed of approximately 1.8 m/min and a solution coating rate of approximately 96 g/min was utilized to imbibe this solution into an ePTFE membrane that was fed from a roll.


A biaxially expanded ePTFE membrane that had not been amorphously locked, and having the following properties was used: thickness=0.0025 mm, density=0.236 g/cc, matrix tensile strength in the strongest direction=386 MPa, matrix tensile strength in the direction orthogonal to the strongest direction=218 MPa, elongation at maximum load in the strongest direction=24%, and elongation at maximum load in the direction orthogonal to the strongest direction=38.1%.


The imbibed ePTFE membrane was restrained in the clamps of a heated, uniaxial tenter frame where the length direction corresponded with the strongest direction of the membrane, and fed into a 2.4 m long heated chamber.


The rails of the tenter frame were positioned to accommodate a 100 mm wide imbibed ePTFE membrane entering the heated chamber, enabling the heated composite to shrink due to the application of heat so that it exited the chamber with an approximate 56 mm width. The line speed was set to provide a dwell time of about 45 seconds within the heated chamber and the material reached a maximum temperature of approximately 180° C., thereby driving off substantially all of the fluorosolvent.


This imbibing process enabled the copolymer to at least partially penetrate the pores of the membrane and to create a coating of the copolymer on the surface of the membrane


The stress of this elastomeric composite was about 43 MPa. The stress-strain curve is shown as FIG. 5 with stress plotted against strain. The stress-strain curve 111 exhibits an inflection point due to the change in slope upon reaching an elongation referred to herein as the stop point 112. In FIG. 5, the intersection of two tangent lines depicts the stop point 112 of the composite material, which is about 45%. The intersection of the tangent lines is depicted by intersection point 50. An estimate of the stop point 112 may be determined in the following manner. The slope of the stress-strain curve 111 prior to reaching the stop point 112 can be approximated by drawing a straight line tangent to the curve as shown as first line 60 in FIG. 5. The slope of the stress-strain curve 111 beyond the stop point can be approximated by drawing a straight line tangent to the stress-strain curve 111 as shown as second line 70 in FIG. 5. The strain corresponding to the intersection of the two tangent lines is an estimation of the stop point 112 for that composite material. It is to be understood that this same technique can be applied to stress-strain curves of other materials, such as membranes and leaflets, of embodiments presented herein.


Four layers of this elastomeric composite were wrapped circumferentially around the mandrel 1101. The elastomeric composite was pierced using sharp pointed tweezers above each of the 48 vent holes.


The support structure 1001, which is a metallic balloon expandable structure, with composite fiber wrapped posts was slid over the elastomeric composite and mandrel 1101 and was positioned as shown in FIG. 8.


A 0.025 mm thick film of the fluoroelastomer previously described was obtained. A 3 mm wide strip of this fluoroelastomer film was positioned on top of the leaflet closed cells 1004 of the support structure 1001. Additional strips of fluoroelastomer film with widths of 10, 15, and 20 mm were sequentially positioned on top of each of the stent frame posts 1006. Eight additional layers of the elastomeric composite were wrapped around the mandrel 1101 and all the previously applied components.


A sacrificial composite material comprising ePTFE and polyimide with a thickness of approximately 0.004 mm was wrapped around the mandrel and previously applied components. Adhesive-backed polyimide tape was used to attach the ePTFE/polyimide composite to the mandrel at each end and to seal the longitudinal seam.


The mandrel 1102 with previously applied components was then mounted in a pressure vessel so that the central cavity 1106 was plumbed to atmosphere. The central cavity 1106 extended from the first end 1102 axially through the mandrel 1101 and communicates to the 48 previously described pocket vent holes 1107 and surface vent holes 1108.


About 414 KPa (60 psi) of helium pressure was applied to the pressure vessel, forcing the ePTFE/fluoroelastomer composite material against the mandrel 1101 and the support structure 1001. Heat was applied to the pressure vessel until the temperature inside the mandrel reached about 264° C., about 55 minutes later. The heat was removed and the pressure vessel was allowed to cool to room temperature. This process thermally bonded the layers of ePTFE/fluoroelastomer composite material to each other and to the support structure 1001. The pressure was released and the mandrel was removed from the pressure vessel. The valve assembly was slid off of the mandrel 1101 and the sacrificial ePTFE/polyimide composite material was removed.


A horizontal slit was made through the ePTFE/elastomer composite material near the upper ring of the support structure 1001. Small sheets of 0.76 mm thick FEP film were pressed against each of the three leaflets and clamped in place using hemostats so that the valve assumed a closed shape. The valve was placed in an oven at 180° C. for 15 minutes while held in this position.


After removing the FEP sheets, the valve leaflets were trimmed to their final length and excess ePTFE/elastomer composite was trimmed around the support structure, which resulted in a valve 800 as shown in FIGS. 9A and 9B showing the leaflets 802.


The performance of the leaflets 802 in this valve 800 were characterized on a real-time pulse duplicator that measured typical anatomical pressures and flows across the valve 800, generating an initial or “zero fatigue” set of data for that particular valve 800. The valve 800 was then transferred to a high-rate fatigue tester and was subjected to approximately 200 million cycles.


The flow performance was characterized by the following process:


The valve 800 was pressed into a silicone annular ring to allow the valve 800 to be subsequently evaluated in a real-time pulse duplicator.


The potted valve 800 was then placed into a real-time left heart flow pulse duplicator system. The flow pulse duplicator system included the following components supplied by VSI Vivitro Systems Inc., Victoria BC, Canada: a Super Pump, Servo Power Amplifier Part Number SPA 3891; a Super Pump Head, Part Number SPH 5891B, 38.320 cm2 cylinder area; a valve station/fixture; a Wave Form Generator, TriPack Part Number TP 2001; a Sensor Interface, Part Number VB 2004; a Sensor Amplifier Component, Part Number AM 9991; and a Square Wave Electro Magnetic Flow Meter, Carolina Medical Electronics Inc., East Bend, N.C., USA.


In general, the flow pulse duplicator system uses a fixed displacement, piston pump to produce a desired fluid flow through the valve 800 under test.


The heart flow pulse duplicator system was adjusted to produce the desired flow, mean pressure, and simulated pulse rate. The valve 800 under test was then cycled for about 5 to 20 minutes.


Pressure and flow data were measured and collected during the test period, including ventricular pressures, aortic pressures, flow rates, and pump piston position.


The valve 800 in this example had a pressure drop of 5.2 mm Hg, EOA of 2.97 and regurgitant fraction of 14.4%


The durability of the leaflets 802 in this example were evaluated in a high rate fatigue tester (Six Position Heart Valve Durability Tester, Part Number M6 was supplied by Dynatek, Galena, Mo.) and was driven by a Dynatek Dalta DC 7000 Controller. This high rate fatigue tester displaces fluid through a valve 800 with a typical cycle rate of about 780 cycles per minute. During the test, the valve 800 can be visually examined using a tuned strobe light. The leaflets 802 were tested to 200 million cycles with no visible signs of holes, tears, or delamination in the leaflets 802.


One of the leaflets 802 was cut from the support structure 1001. The elastomer was removed as described in the test method set forth above. It is noted that the elastomer does not need to be fully removed from the leaflet 802 to reveal the serpentine fibrils. FIG. 2 is an SEM of the surface of the leaflet 802 taken at 10,000× magnification. The leaflet 802 was stretched 23% from the relaxed length so as to open the structure to more clearly see the fibrils. A sufficient amount of elastomer was removed to reveal the presence of serpentine fibrils, that is, fibrils extending in a serpentine shape.


The percent unrecoverable strain energy density of the leaflet 802 was determined to be about 86.6% and is depicted by the area bound by the elongation and return curves in FIG. 4, which indicated the elastic property of the leaflet 802. In addition, it was determined that the leaflet 802 had an ultimate tensile strength of about 53 MPa.


While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modification, and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as fall within the scope of the invention and the limits of the appended claims.

Claims
  • 1. A method of forming a leaflet of a prosthetic valve, comprising: providing a composite material comprising an expanded fluoropolymer membrane that is retracted, substantially wrinkle-free, and has serpentine fibrils, the composite material including an elastomer or elastomeric material, the expanded fluoropolymer membrane including a plurality of pores substantially filled with the elastomer or elastomeric material; andwrapping the composite material into contact with itself to define an axial seam and adhering the composite material to itself along the axial seam.
  • 2. The method of claim 1, wherein the fluoropolymer is polytetrafluoroethylene.
  • 3. The method of claim 1, wherein the expanded fluoropolymer membrane comprises a microstructure of substantially only serpentine fibrils.
  • 4. The method of claim 1, wherein the elastomer or elastomeric material is selected from the group consisting of perfluoromethylvinyl ether-tetrafluoroethylene copolymers, perfluoro (alkyl vinyl ether)-tetrafluoroethylene copolymers, silicones and polyurethanes.
  • 5. The method of claim 1, wherein the leaflet has a ratio of thickness to number of layers of the composite material of less than about 5 μm.
  • 6. The method of claim 1, further comprising shaping the composite material into at least one leaflet, wherein elastic properties are present in an axial direction of the at least one leaflet.
  • 7. The method of claim 1, further comprising operatively coupling the composite material to a support structure such that the composite material forms at least one leaflet that is movable between closed and open configurations relative to the support structure.
  • 8. A method of making a prosthetic valve, the method comprising: providing a composite material including an expanded fluoropolymer membrane that is a retracted, substantially wrinkle-free membrane having serpentine fibrils that defines a plurality of pores and an elastomer or elastomeric material disposed in the pores, the expanded fluoropolymer membrane including the plurality of pores substantially filled with the elastomer or elastomeric material; andoperatively coupling the composite material to a support structure to form the composite material into a leaflet cyclable between a closed configuration to substantially prevent blood flow through the prosthetic valve and an open configuration to allow blood flow through the prosthetic valve, the leaflet including at least one layer of the composite material.
  • 9. The method of claim 8, wherein operatively coupling the composite material to the support structure to form the composite material into a leaflet includes forming the leaflet such that the composite material is substantially free of wrinkles when the leaflet is cycled between the closed configuration and the open configuration.
  • 10. The method of claim 8, wherein the expanded fluoropolymer membrane is polytetrafluoroethylene.
  • 11. The method of claim 8, wherein the expanded fluoropolymer membrane comprises a microstructure of primarily serpentine fibrils.
  • 12. The method of claim 8, wherein the expanded fluoropolymer membrane comprises a plurality of serpentine fibrils.
  • 13. The method of claim 8, wherein the composite material has a plurality of layers and the leaflet formed by coupling the composite material to the support structure has a ratio of thickness to number of layers of the composite material of less than about 5 micrometers per layer.
  • 14. The method of claim 8, wherein the leaflet is formed such that elastic properties are present in an axial direction of the leaflet.
  • 15. The method of claim 8, wherein the elastomer or elastomeric material is selected from the group consisting of perfluoromethylvinyl ether-tetrafluoroethylene copolymers, perfluoro (alkyl vinyl ether)-tetrafluoroethylene copolymers, silicones and polyurethanes.
  • 16. A method of forming a leaflet of a prosthetic valve, comprising: providing a composite material comprising an expanded fluoropolymer membrane that is a retracted, substantially wrinkle-free membrane having serpentine fibrils and an elastomer or elastomeric material, the expanded fluoropolymer membrane including a plurality of pores substantially filled with the elastomer or elastomeric material; andforming the composite material into a leaflet, the composite material exhibiting an increase in stiffness when elongated to at least about 30% strain.
  • 17. The method of claim 16, wherein the composite material exhibits an increase in stiffness when elongated to at least about 40% strain.
  • 18. The method of claim 16, wherein the composite material exhibits an increase in stiffness when elongated to at least about 45% strain.
  • 19. The method of claim 16, wherein the composite material exhibits an increase in stiffness when elongated to at least about 50% strain.
  • 20. The method of claim 16, wherein the composite material exhibits an increase in stiffness when elongated to at least about 55% strain.
  • 21. The method of claim 16, wherein the expanded fluoropolymer membrane comprises a microstructure primarily formed of serpentine fibrils.
  • 22. The method of claim 16, wherein the elastomer or elastomeric material is selected from the group consisting of perfluoromethylvinyl ether-tetrafluoroethylene copolymers, perfluoro (alkyl vinyl ether)-tetrafluoroethylene copolymers, silicones and polyurethanes.
  • 23. The method of claim 16, wherein the elastomer or elastomeric material is selected from the group consisting of perfluoromethylvinyl ether-tetrafluoroethylene copolymers, perfluoro (alkyl vinyl ether)-tetrafluoroethylene copolymers, silicones and polyurethanes.
  • 24. A method of forming a leaflet of a prosthetic valve, comprising: providing a composite material comprising an expanded fluoropolymer membrane that is retracted, the expanded fluoropolymer membrane including a plurality of pores substantially filled with an elastomer; andforming a layered construct using the composite material.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a divisional of U.S. patent application Ser. No. 14/181,965, filed Feb. 17, 2014, which claims the benefit of U.S. Provisional Application 61/779,891, filed Mar. 13, 2013, both of which are incorporated herein by reference in their entireties for all purposes. This application is also a continuation-in-part of U.S. patent application Ser. No. 13/485,823, filed May 31, 2012, now U.S. Pat. No. 8,945,212, issued Feb. 3, 2015, and is also a continuation-in-part of U.S. patent application Ser. No. 13/078,774, filed Apr. 1, 2011, now U.S. Pat. No. 8,961,599, granted Feb. 24, 2015, both of which are incorporated herein by reference in their entireties for all purposes.

US Referenced Citations (477)
Number Name Date Kind
654799 Levett Jul 1900 A
1851314 Knoche Mar 1932 A
3625451 Anderson Dec 1971 A
3915167 Waterman Oct 1975 A
3953566 Gore Apr 1976 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4339831 Johnson Jul 1982 A
4340091 Skelton et al. Jul 1982 A
4349498 Ellis et al. Sep 1982 A
4425908 Simon Jan 1984 A
4626255 Reichart et al. Dec 1986 A
4629459 Ionescu et al. Dec 1986 A
4655246 Phlipot et al. Apr 1987 A
4692369 Nomi Sep 1987 A
4731074 Rousseau et al. Mar 1988 A
4851000 Gupta Jul 1989 A
4858810 Intlekofer et al. Aug 1989 A
4877661 House et al. Oct 1989 A
4955899 Della Corna et al. Sep 1990 A
5026513 House et al. Jun 1991 A
5071609 Roger et al. Dec 1991 A
5217486 Rice et al. Jun 1993 A
5325746 Anderson Jul 1994 A
5344427 Cottenceau et al. Sep 1994 A
5397355 Marin et al. Mar 1995 A
5476589 Bacino Dec 1995 A
5491704 Duron Feb 1996 A
5527338 Purdy Jun 1996 A
5534007 St. Germain et al. Jul 1996 A
5549663 Cottone Aug 1996 A
5554183 Nazari Sep 1996 A
5562726 Chuter Oct 1996 A
5693083 Baker et al. Dec 1997 A
5707376 Kavteladze et al. Jan 1998 A
5708044 Branca Jan 1998 A
5709704 Nott et al. Jan 1998 A
5713917 Leonhardt et al. Feb 1998 A
5713948 Uflacker Feb 1998 A
5718973 Lewis et al. Feb 1998 A
5720776 Chuter et al. Feb 1998 A
5725552 Kotula et al. Mar 1998 A
5759192 Saunders Jun 1998 A
5769884 Solovay Jun 1998 A
5772884 Tanaka et al. Jun 1998 A
5776141 Klein et al. Jul 1998 A
5776186 Uflacker Jul 1998 A
5782909 Quiachon et al. Jul 1998 A
5824043 Cottone Oct 1998 A
5824050 Karwoski et al. Oct 1998 A
5843158 Lenker et al. Dec 1998 A
5843161 Solovay Dec 1998 A
5843162 Inoue Dec 1998 A
5904703 Gilson May 1999 A
5935162 Dang Aug 1999 A
5961546 Robinson et al. Oct 1999 A
6010529 Herweck et al. Jan 2000 A
6013093 Nott et al. Jan 2000 A
6013854 Moriuchi Jan 2000 A
6015431 Thornton et al. Jan 2000 A
6019785 Strecker Feb 2000 A
6027779 Campbell et al. Feb 2000 A
6042588 Munsinger et al. Mar 2000 A
6042606 Frantzen Mar 2000 A
6143021 Staehle Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6165195 Wilson Dec 2000 A
6174331 Moe et al. Jan 2001 B1
6190406 Duerig et al. Feb 2001 B1
6214025 Thistle et al. Apr 2001 B1
6224627 Armstrong et al. May 2001 B1
6231561 Frazier et al. May 2001 B1
6231581 Shank et al. May 2001 B1
6231589 Wessman et al. May 2001 B1
6245012 Kleshinski Jun 2001 B1
6245939 Yu Wei et al. Jun 2001 B1
6261320 Tam et al. Jul 2001 B1
6264671 Stack et al. Jul 2001 B1
6273900 Nott et al. Aug 2001 B1
6283994 Moe et al. Sep 2001 B1
6322585 Khosravi et al. Nov 2001 B1
6328727 Frazier et al. Dec 2001 B1
6346117 Greenhalgh Feb 2002 B1
6352561 Leopold et al. Mar 2002 B1
6451396 Zumbrum et al. Mar 2002 B1
6372870 Kitahara et al. Apr 2002 B1
6436132 Patel et al. Aug 2002 B1
6451051 Drasler et al. Sep 2002 B2
6485513 Fan Nov 2002 B1
6488701 Nolting et al. Dec 2002 B1
6491704 Gifford et al. Dec 2002 B2
6524335 Hartley et al. Feb 2003 B1
6527779 Rourke Mar 2003 B1
6541589 Baillie Apr 2003 B1
6551303 Van et al. Apr 2003 B1
6551350 Thornton et al. Apr 2003 B1
6562069 Cai et al. May 2003 B2
6572643 Gharibadeh Jun 2003 B1
6572646 Boylan et al. Jun 2003 B1
6620190 Colone Sep 2003 B1
6626939 Burnside et al. Sep 2003 B1
6652556 Vantassel et al. Nov 2003 B1
6666885 Moe Dec 2003 B2
6673455 Zumbrum et al. Jan 2004 B2
6689150 Vantassel et al. Feb 2004 B1
6705563 Luo et al. Mar 2004 B2
6712836 Berg et al. Mar 2004 B1
6712842 Gifford et al. Mar 2004 B1
6726715 Sutherland Apr 2004 B2
6730108 Van et al. May 2004 B2
6730120 Berg et al. May 2004 B2
6743210 Hart et al. Jun 2004 B2
6746472 Frazier et al. Jun 2004 B2
6755854 Gillick et al. Jun 2004 B2
6755856 Seibold et al. Jun 2004 B2
6755857 Peterson et al. Jun 2004 B2
6758858 McCrea et al. Jul 2004 B2
6770579 Dawson Aug 2004 B1
6776604 Chobotov et al. Aug 2004 B1
6827731 Armstrong et al. Dec 2004 B2
6866669 Buzzard et al. Mar 2005 B2
6884259 Tran et al. Apr 2005 B2
6926732 Derus et al. Aug 2005 B2
6939352 Buzzard et al. Sep 2005 B2
6945990 Greenan Sep 2005 B2
6949113 Van et al. Sep 2005 B2
6953332 Kurk et al. Oct 2005 B1
6974471 Van et al. Dec 2005 B2
6994092 Van et al. Feb 2006 B2
7033368 Rourke Apr 2006 B2
7044134 Khairkhahan et al. May 2006 B2
7049380 Chang May 2006 B1
7052511 Weldon et al. May 2006 B2
7066951 Chobotov Jun 2006 B2
7083642 Sirhan et al. Aug 2006 B2
7105018 Yip et al. Sep 2006 B1
7122050 Randall et al. Oct 2006 B2
7128073 Van et al. Oct 2006 B1
7147657 Chiang et al. Dec 2006 B2
7169160 Middleman et al. Jan 2007 B1
7198636 Cully et al. Apr 2007 B2
7208003 Davis et al. Apr 2007 B2
7238200 Lee et al. Jul 2007 B2
7252680 Freitag Aug 2007 B2
7306729 Bacino et al. Dec 2007 B2
7331992 Randall et al. Feb 2008 B2
7396359 Derowe et al. Jul 2008 B1
7419678 Falotico Sep 2008 B2
7448122 Kokish et al. Nov 2008 B1
7462675 Chang et al. Dec 2008 B2
7531611 Sabol et al. May 2009 B2
7555034 Shin et al. Jun 2009 B2
7566336 Corcoran et al. Jul 2009 B2
7572289 Sisken et al. Aug 2009 B2
7601159 Ewers et al. Oct 2009 B2
7611528 Goodson et al. Nov 2009 B2
7628803 Pavcnik et al. Dec 2009 B2
7655034 Mitchell et al. Feb 2010 B2
7678123 Chanduszko Mar 2010 B2
7771455 Ken Aug 2010 B2
7789908 Sowinski Sep 2010 B2
7803186 Li et al. Sep 2010 B1
7811314 Fierens et al. Oct 2010 B2
7815591 Levine et al. Oct 2010 B2
7815763 Fierens et al. Oct 2010 B2
7833565 O'Connor Nov 2010 B2
7846179 Belef et al. Dec 2010 B2
7887580 Randall et al. Feb 2011 B2
7927364 Fierens et al. Apr 2011 B2
7927365 Fierens et al. Apr 2011 B2
7935141 Randall et al. May 2011 B2
7967829 Gunderson et al. Jun 2011 B2
7976575 Hartley Jul 2011 B2
7998189 Koelbel et al. Aug 2011 B2
8029557 Sobrino-Serrano Oct 2011 B2
8029559 Sisken et al. Oct 2011 B2
8029563 House et al. Oct 2011 B2
8048440 Chang et al. Nov 2011 B2
8062349 Moore et al. Nov 2011 B2
8080032 Van et al. Dec 2011 B2
8157810 Case et al. Apr 2012 B2
8167935 McGuckin et al. May 2012 B2
8231650 Cully et al. Jul 2012 B2
8241350 Randall et al. Aug 2012 B2
8273105 Cohen et al. Sep 2012 B2
8287583 Laduca et al. Oct 2012 B2
8349000 Schreck Jan 2013 B2
8424166 Dorneman et al. Apr 2013 B2
8449595 Ouellette et al. May 2013 B2
8469990 McGuckin et al. Jun 2013 B2
8475512 Hunt Jul 2013 B2
8523897 Van et al. Sep 2013 B2
8529597 Linder et al. Sep 2013 B2
8585757 Agathos Nov 2013 B2
8637144 Ford Jan 2014 B2
8685055 Vantassel et al. Apr 2014 B2
8709077 Schreck Apr 2014 B2
8801746 Kreidler et al. Aug 2014 B1
8834519 Van et al. Sep 2014 B2
8870947 Shaw Oct 2014 B2
8945212 Bruchman et al. Feb 2015 B2
8961599 Bruchman et al. Feb 2015 B2
9109310 Baaijens et al. Aug 2015 B2
9254204 Roeder et al. Feb 2016 B2
9314249 Kreidler et al. Apr 2016 B2
9504565 Armstrong Nov 2016 B2
9554806 Larsen et al. Jan 2017 B2
9554900 Bruchman et al. Jan 2017 B2
9597086 Larsen et al. Mar 2017 B2
9743932 Amplatz et al. Aug 2017 B2
9744033 Bruchman et al. Aug 2017 B2
9770327 Bruchman et al. Sep 2017 B2
9795475 Bruchman et al. Oct 2017 B2
9801712 Bruchman et al. Oct 2017 B2
10022219 Bruchman et al. Jul 2018 B2
10342658 Bruchman et al. Jul 2019 B2
10470878 Bruchman et al. Nov 2019 B2
20010037142 Stelter et al. Nov 2001 A1
20010051824 Hopkins et al. Dec 2001 A1
20020007208 Strecker Jan 2002 A1
20020029077 Leopold et al. Mar 2002 A1
20020045936 Moe Apr 2002 A1
20020055773 Campbell et al. May 2002 A1
20020091439 Baker et al. Jul 2002 A1
20020099431 Armstrong et al. Jul 2002 A1
20020151953 Chobotov et al. Oct 2002 A1
20020198588 Armstrong et al. Dec 2002 A1
20020198594 Schreck Dec 2002 A1
20030004559 Lentz et al. Jan 2003 A1
20030004560 Chobotov et al. Jan 2003 A1
20030012905 Zumbrum et al. Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030055492 Shaolian et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030055496 Cai et al. Mar 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030060871 Hill et al. Mar 2003 A1
20030097175 O'Connor et al. May 2003 A1
20030098383 Luo et al. May 2003 A1
20030114917 Holloway et al. Jun 2003 A1
20030139806 Haverkost et al. Jul 2003 A1
20030149467 Linder et al. Aug 2003 A1
20030181942 Sutton et al. Sep 2003 A1
20030211264 Farnsworth et al. Nov 2003 A1
20030229394 Ogle et al. Dec 2003 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040024442 Sowinski et al. Feb 2004 A1
20040024448 Chang et al. Feb 2004 A1
20040034366 Van et al. Feb 2004 A1
20040044361 Frazier et al. Mar 2004 A1
20040054396 Hartley et al. Mar 2004 A1
20040073289 Hartley Apr 2004 A1
20040093070 Hojeibane et al. May 2004 A1
20040122503 Campbell et al. Jun 2004 A1
20040138734 Chobotov et al. Jul 2004 A1
20040143315 Bruun et al. Jul 2004 A1
20040167619 Case et al. Aug 2004 A1
20040176839 Huynh et al. Sep 2004 A1
20040260393 Rahdert et al. Dec 2004 A1
20050038470 Van et al. Feb 2005 A1
20050049667 Arbefeuille et al. Mar 2005 A1
20050070820 Boutillette et al. Mar 2005 A1
20050080476 Gunderson et al. Apr 2005 A1
20050085890 Rasmussen et al. Apr 2005 A1
20050113861 Corcoran et al. May 2005 A1
20050125031 Pipenhagen et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050240257 Ishimaru et al. Oct 2005 A1
20050261765 Liddicoat Nov 2005 A1
20050283224 King Dec 2005 A1
20050288767 Kujawski et al. Dec 2005 A1
20060004433 Greenberg et al. Jan 2006 A1
20060015171 Armstrong Jan 2006 A1
20060036311 Nakayama et al. Feb 2006 A1
20060058833 Vancamp et al. Mar 2006 A1
20060058889 Case et al. Mar 2006 A1
20060135947 Soltesz et al. Jun 2006 A1
20060155366 Laduca et al. Jul 2006 A1
20060190074 Hill et al. Aug 2006 A1
20060254569 Chipman Nov 2006 A1
20060259133 Sowinski et al. Nov 2006 A1
20060264980 Khairkhahan et al. Nov 2006 A1
20060265053 Hunt Nov 2006 A1
20060276883 Greenberg et al. Dec 2006 A1
20060276888 Lee et al. Dec 2006 A1
20060290027 O'Connor et al. Dec 2006 A1
20070012624 Bacino et al. Jan 2007 A1
20070027528 Agnew Feb 2007 A1
20070027535 Purdy et al. Feb 2007 A1
20070060999 Randall et al. Mar 2007 A1
20070066993 Kreidler Mar 2007 A1
20070067021 Haverkost et al. Mar 2007 A1
20070088424 Greenberg et al. Apr 2007 A1
20070100427 Perouse May 2007 A1
20070118209 Strecker May 2007 A1
20070118210 Pinchuk May 2007 A1
20070129786 Beach et al. Jun 2007 A1
20070162048 Quinn et al. Jul 2007 A1
20070167955 Arnault et al. Jul 2007 A1
20070198077 Cully et al. Aug 2007 A1
20070198078 Berra et al. Aug 2007 A1
20070208421 Quigley Sep 2007 A1
20070213800 Fierens et al. Sep 2007 A1
20070219467 Clark et al. Sep 2007 A1
20070248640 Karabey et al. Oct 2007 A1
20070249980 Carrez et al. Oct 2007 A1
20070250146 Cully et al. Oct 2007 A1
20070250153 Cully et al. Oct 2007 A1
20070254012 Ludwig et al. Nov 2007 A1
20070255390 Ducke et al. Nov 2007 A1
20070270891 McGuckin, Jr. Nov 2007 A1
20070288087 Fearnot et al. Dec 2007 A1
20080027529 Hartley et al. Jan 2008 A1
20080033527 Nunez et al. Feb 2008 A1
20080033534 Cook et al. Feb 2008 A1
20080039925 Ishimaru et al. Feb 2008 A1
20080051876 Ta et al. Feb 2008 A1
20080091261 Long et al. Apr 2008 A1
20080114440 Hlavka et al. May 2008 A1
20080119943 Armstrong et al. May 2008 A1
20080125711 Alpini et al. May 2008 A1
20080133004 White Jun 2008 A1
20080147111 Johnson et al. Jun 2008 A1
20080178434 Bulanda Jul 2008 A1
20080200977 Paul et al. Aug 2008 A1
20080208329 Bishop et al. Aug 2008 A1
20080269785 Lampropoulos et al. Oct 2008 A1
20080319531 Doran et al. Dec 2008 A1
20090004239 Ladet et al. Jan 2009 A1
20090005854 Huang et al. Jan 2009 A1
20090030499 Bebb et al. Jan 2009 A1
20090036976 Beach et al. Feb 2009 A1
20090043373 Arnault de la Menardiere et al. Feb 2009 A1
20090048656 Wen Feb 2009 A1
20090054723 Khairkhahan et al. Feb 2009 A1
20090062838 Brumleve et al. Mar 2009 A1
20090082844 Zacharias et al. Mar 2009 A1
20090099596 McGuckin et al. Apr 2009 A1
20090099640 Weng Apr 2009 A1
20090112249 Miles et al. Apr 2009 A1
20090157175 Benichou Jun 2009 A1
20090171386 Amplatz et al. Jul 2009 A1
20090182413 Burkart et al. Jul 2009 A1
20090187197 Roeber et al. Jul 2009 A1
20090216308 Hartley Aug 2009 A1
20090216321 Osborne et al. Aug 2009 A1
20090259291 Kolbel et al. Oct 2009 A1
20100011564 Millwee et al. Jan 2010 A1
20100016943 Chobotov Jan 2010 A1
20100023048 Mach Jan 2010 A1
20100023114 Chambers et al. Jan 2010 A1
20100057195 Roeder et al. Mar 2010 A1
20100094394 Beach et al. Apr 2010 A1
20100094401 Kolbel et al. Apr 2010 A1
20100094405 Cottone Apr 2010 A1
20100106240 Duggal et al. Apr 2010 A1
20100159171 Clough Jun 2010 A1
20100190254 Chian et al. Jul 2010 A1
20100211052 Brown et al. Aug 2010 A1
20100248324 Xu et al. Sep 2010 A1
20100249922 Li et al. Sep 2010 A1
20100280591 Shin et al. Nov 2010 A1
20110039690 Niu Feb 2011 A1
20110040366 Goetz et al. Feb 2011 A1
20110049757 O'Connor Mar 2011 A1
20110054515 Bridgeman et al. Mar 2011 A1
20110054519 Neuss Mar 2011 A1
20110064781 Cleek et al. Mar 2011 A1
20110066221 White et al. Mar 2011 A1
20110125252 Goddard et al. May 2011 A1
20110130821 Styrc Jun 2011 A1
20110142804 Gaudette et al. Jun 2011 A1
20110218619 Benichou et al. Sep 2011 A1
20110250689 Baaijens et al. Oct 2011 A1
20110311746 Ma et al. Dec 2011 A1
20110313503 Berra et al. Dec 2011 A1
20120022630 Wubbeling Jan 2012 A1
20120022638 Leewood et al. Jan 2012 A1
20120046652 Sokel Feb 2012 A1
20120058100 Shastri et al. Mar 2012 A1
20120061314 Choi et al. Mar 2012 A1
20120065667 Javois et al. Mar 2012 A1
20120078357 Conklin Mar 2012 A1
20120116496 Chuter et al. May 2012 A1
20120123529 Levi et al. May 2012 A1
20120123530 Carpentier et al. May 2012 A1
20120129150 Carbonell May 2012 A1
20120130473 Norris et al. May 2012 A1
20120130474 Buckley May 2012 A1
20120130475 Shaw May 2012 A1
20120143242 Masters Jun 2012 A1
20120143305 Berra et al. Jun 2012 A1
20120172927 Campbell et al. Jul 2012 A1
20120172965 Kratzberg et al. Jul 2012 A1
20120172968 Chuter et al. Jul 2012 A1
20120253450 Case et al. Oct 2012 A1
20120253453 Bruchman Oct 2012 A1
20120283585 Werneth et al. Nov 2012 A1
20120283773 Van et al. Nov 2012 A1
20120290082 Quint et al. Nov 2012 A1
20120296360 Norris et al. Nov 2012 A1
20120296418 Bonyuet et al. Nov 2012 A1
20120323211 Ogle et al. Dec 2012 A1
20120323270 Lee Dec 2012 A1
20120323315 Bruchman et al. Dec 2012 A1
20130023981 Dierking et al. Jan 2013 A1
20130046371 Greenberg et al. Feb 2013 A1
20130073029 Shaw Mar 2013 A1
20130123896 Bloss et al. May 2013 A1
20130123908 Hinchliffe et al. May 2013 A1
20130138138 Clark et al. May 2013 A1
20130150947 Kaufman et al. Jun 2013 A1
20130158647 Norris et al. Jun 2013 A1
20130166021 Bruchman et al. Jun 2013 A1
20130178889 Miles et al. Jul 2013 A1
20130184807 Kovach et al. Jul 2013 A1
20130197631 Bruchman et al. Aug 2013 A1
20130245666 Larsen et al. Sep 2013 A1
20130245742 Norris Sep 2013 A1
20130296912 Ottma Nov 2013 A1
20130310924 Groothuis et al. Nov 2013 A1
20130331929 Mitra et al. Dec 2013 A1
20140005773 Wheatley Jan 2014 A1
20140012303 Heipl Jan 2014 A1
20140018841 Peiffer et al. Jan 2014 A1
20140031927 Bruchman et al. Jan 2014 A1
20140046360 Van et al. Feb 2014 A1
20140135817 Tischler et al. May 2014 A1
20140135897 Cully et al. May 2014 A1
20140142617 Larsen et al. May 2014 A1
20140163671 Bruchman et al. Jun 2014 A1
20140163673 Bruchman et al. Jun 2014 A1
20140172066 Goepfrich et al. Jun 2014 A1
20140172080 Bruchman et al. Jun 2014 A1
20140172081 Bruchman et al. Jun 2014 A1
20140172082 Bruchman et al. Jun 2014 A1
20140172083 Bruchman et al. Jun 2014 A1
20140180400 Bruchman et al. Jun 2014 A1
20140180402 Bruchman et al. Jun 2014 A1
20140188220 Seguin Jul 2014 A1
20140253453 Lo Sep 2014 A1
20140288642 Yoshida et al. Sep 2014 A1
20140296908 Ottma et al. Oct 2014 A1
20140296909 Heipl et al. Oct 2014 A1
20140350592 Kreidler et al. Nov 2014 A1
20140379019 Larsen et al. Dec 2014 A1
20150005809 Ayres et al. Jan 2015 A1
20150005810 Center et al. Jan 2015 A1
20150051695 Shaw Feb 2015 A1
20150135537 Bruchman et al. May 2015 A1
20150223757 Werneth et al. Aug 2015 A1
20150224231 Bruchman et al. Aug 2015 A1
20150257875 Bruchman Sep 2015 A1
20150257876 Bruchman et al. Sep 2015 A1
20150265744 Baaijens Sep 2015 A1
20150283297 Baaijens et al. Oct 2015 A1
20150305749 Alferness Oct 2015 A1
20150305862 Bruchman et al. Oct 2015 A1
20150306277 Pathak et al. Oct 2015 A1
20150366663 Bruchman et al. Dec 2015 A1
20160008133 Day et al. Jan 2016 A9
20160067374 Puckett et al. Mar 2016 A1
20160074161 Bennett Mar 2016 A1
20160100939 Armstrong Apr 2016 A1
20160175095 Dienno et al. Jun 2016 A1
20160175096 Dienno Jun 2016 A1
20160317299 Alkhatib Nov 2016 A1
20160331382 Center et al. Nov 2016 A1
20170042674 Armstrong Feb 2017 A1
20170181751 Larsen et al. Jun 2017 A1
20180008406 Bruchman et al. Jan 2018 A1
20180200050 Bruchman et al. Jul 2018 A1
20190110880 Fox et al. Apr 2019 A1
20190114303 Peloski Apr 2019 A1
20190258641 Peloski Aug 2019 A1
20190269506 Bruchman et al. Sep 2019 A1
Foreign Referenced Citations (125)
Number Date Country
1342056 Mar 2002 CN
2820130 Sep 2006 CN
2904980 May 2007 CN
101304693 Nov 2008 CN
101554343 Oct 2009 CN
101780306 Jul 2010 CN
101965161 Feb 2011 CN
201879866 Jun 2011 CN
201930098 Aug 2011 CN
102908174 Feb 2013 CN
103347467 Oct 2013 CN
102014102725 Sep 2015 DE
0150608 Aug 1985 EP
0293090 Nov 1988 EP
0313263 Apr 1989 EP
0664107 Jul 1995 EP
0679372 Nov 1995 EP
0773971 May 1997 EP
0815806 Jan 1998 EP
0893108 Jan 1999 EP
1318775 Jun 2003 EP
1977719 Oct 2008 EP
2074953 Jul 2009 EP
2481381 Aug 2012 EP
2596754 May 2013 EP
2896405 Jul 2007 FR
2344054 May 2000 GB
02-000645 Jan 1990 JP
08-126704 May 1996 JP
H09501759 Feb 1997 JP
09-241412 Sep 1997 JP
11-290448 Oct 1999 JP
2001-506902 May 2001 JP
2002-503114 Jan 2002 JP
2002-518086 Jun 2002 JP
2004-510471 Apr 2004 JP
2004-167239 Jun 2004 JP
2004-188219 Jul 2004 JP
2005530549 Oct 2005 JP
2007-502689 Feb 2007 JP
2007-518465 Jul 2007 JP
2008506459 Mar 2008 JP
2008-531117 Aug 2008 JP
2009-542421 Dec 2009 JP
2010-527742 Aug 2010 JP
2010-535075 Nov 2010 JP
2011-005292 Jan 2011 JP
2011-509117 Mar 2011 JP
2011-511693 Apr 2011 JP
2011-516202 May 2011 JP
2014-501563 Jan 2014 JP
2014-501565 Jan 2014 JP
2014-502180 Jan 2014 JP
2014-533189 Dec 2014 JP
2124986 Jul 1996 RU
WO-9505555 Feb 1995 WO
WO-9528899 Nov 1995 WO
9618361 Jun 1996 WO
WO-97010871 Mar 1997 WO
9748350 Dec 1997 WO
9826731 Jun 1998 WO
9965420 Dec 1999 WO
0013613 Mar 2000 WO
WO-0041649 Jul 2000 WO
0062716 Oct 2000 WO
0121109 Mar 2001 WO
0130266 May 2001 WO
WO-0174272 Oct 2001 WO
0224118 Mar 2002 WO
0224119 Mar 2002 WO
0228317 Apr 2002 WO
WO-02060506 Aug 2002 WO
WO-02100454 Dec 2002 WO
0347468 Jun 2003 WO
WO-2004000375 Dec 2003 WO
2005072652 Aug 2005 WO
2006007389 Jan 2006 WO
WO-2006000763 Jan 2006 WO
WO-2006019626 Feb 2006 WO
2006091382 Aug 2006 WO
2006127756 Nov 2006 WO
WO-2007002320 Jan 2007 WO
WO-2007016251 Feb 2007 WO
2007092354 Aug 2007 WO
2008006003 Jan 2008 WO
WO-2008028964 Mar 2008 WO
WO-2008036870 Mar 2008 WO
2008047092 Apr 2008 WO
WO-2008049045 Apr 2008 WO
2008063464 May 2008 WO
WO-2009017827 Feb 2009 WO
WO-2009038761 Mar 2009 WO
2009045332 Apr 2009 WO
2009088905 Jul 2009 WO
2009102441 Aug 2009 WO
WO-2009100210 Aug 2009 WO
2009126227 Oct 2009 WO
2009148594 Dec 2009 WO
WO-2009149462 Dec 2009 WO
2010001012 Jan 2010 WO
WO-2010006783 Jan 2010 WO
2010024881 Mar 2010 WO
WO-2010030766 Mar 2010 WO
2010041038 Apr 2010 WO
2010044854 Apr 2010 WO
2010063795 Jun 2010 WO
2010081041 Jul 2010 WO
2010090699 Aug 2010 WO
2010105195 Sep 2010 WO
WO-2010132707 Nov 2010 WO
2011031981 Mar 2011 WO
2011062858 May 2011 WO
WO-2011065809 Jun 2011 WO
2012068257 May 2012 WO
2012109297 Aug 2012 WO
2012135603 Oct 2012 WO
2012163257 Dec 2012 WO
2012167131 Dec 2012 WO
2013040431 Mar 2013 WO
2013137977 Sep 2013 WO
2015085138 Jun 2015 WO
2015132668 Sep 2015 WO
2016028591 Feb 2016 WO
2016044223 Mar 2016 WO
2016183495 Nov 2016 WO
Non-Patent Literature Citations (34)
Entry
Annex to Form PCT/ISA/206 Communication Relating to the Results of the Partial International Search PCT/US2014/016550 dated Apr. 8, 2014, corresponding to U.S. Appl. No. 13/798,595; 3 pages.
International Search Report and Written Opinion for PCT/US2011/061165 dated Oct. 1, 2012, corresponding to U.S. Appl. No. 13/298,060.
International Search Report and Written Opinion for PCT/US2012/031417 dated Oct. 18, 2012, corresponding to U.S. Appl. No. 13/078,774.
International Search Report and Written Opinion for PCT/US2012/040529 dated Nov. 14, 2012 corresponding to U.S. Appl. No. 13/485,823.
International Search Report and Written Opinion for PCT/US2012/064908 dated Feb. 4, 2013, corresponding to U.S. Appl. No. 13/675,730, 11 pages.
International Search Report and Written Opinion for PCT/US2012/064910 dated Feb. 1, 2013, corresponding to U.S. Appl. No. 13/675,764, 8 pages.
International Search Report and Written Opinion for PCT/US2012/066518, dated Feb. 4, 2013, corresponding to U.S. Appl. No. 13/351,052, 12 pages.
International Search Report and Written Opinion for PCT/US2014/016550 dated Jul. 2, 2014, corresponding to U.S. Appl. No. 13/798,595; 9 pages.
International Search Report and Written Opinion for PCT/US2014/016581 dated Apr. 8, 2014, corresponding to U.S. Appl. No. 13/801,701, 4 pages.
International Search Report and Written Opinion for PCT/US2014/016807 dated May 30, 2014, corresponding to U.S. Appl. No. 14/181,965, 4 pages.
International Search Report and Written Opinion for PCT/US2015/042530 dated Oct. 6, 2015, corresponding to U.S. Appl. No. 14/622,599, 3 pages.
International Search Report for PCT/US2012/065066, dated Nov. 11, 2013, corresponding to U.S. Appl. No. 13/675,959, 1 0 pages.
Nakayama, Yasuhide. Microporous Stent Achieves Brain Aneurysm Occlusion Without Disturbing Branching Flow. NeuroNews Nov. 2012; 8:1-2.
Partial International Search Report for PCT/US2012/065066, dated Jul. 1, 2013, corresponding to U.S. Appl. No. 13/675,959, 3 pages.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2012/031417, dated Oct. 10, 2013, 5 pages.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2012/040529, dated Dec. 12, 2013, 13 pages.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/016550, dated Sep. 24, 2015, 16 pages.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/016581, dated Sep. 24, 2015, 8 pages.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/016794, dated Sep. 24, 2015, 7 pages.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/016807, dated Sep. 24, 2015, 8 pages.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/017118, dated Sep. 24, 2015, 9 pages.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2015/042530, dated Aug. 24, 2017, 9 pages.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2016/032487, dated Nov. 23, 2017, 13 pages.
International Search Report and Written Opinion for PCT/US2012/061928 dated Jan. 22, 2013, corresponding to U.S. Appl. No. 13/658,597, 8 pages.
International Search Report and Written Opinion for PCT/US2014/066153 dated Feb. 17, 2015, corresponding to U.S. Appl. No. 14/084,592, 5 pages.
International Search Report and Written Opinion from PCT/US2016/032487, dated Dec. 14, 2016, 20 pages.
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/017118, dated Jun. 6, 2014, 12 pages.
International Search Report for PCT/US2014/016794 dated Jun. 6, 2014, corresponding to U.S. Appl. No. 14/182,044, 6 pages.
International Written Opinion received for PCT Patent Application No. PCT/US2014/016794, dated Jun. 6, 2014, 5 pages.
European Search Report and Search Opinion Received for EP Application No. 19179823.0, dated Oct. 1, 2019, 10 pages.
International Preliminary Report on Patentability for PCT/US2012/055445 dated Mar 18, 2014, 9 pages.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/044258, dated Jan. 7, 2016, 7 pages.
International Written Opinion received for PCT Patent Application No. PCT/US14/044258, dated Oct. 29, 2014, 5 pages.
Nishi S, Nakayama Y, Ishibashi-Ueda H, Okamoto Y, Yoshida M. Development of microporous self-expanding stent grafts for treating cerebral aneurysms: designing micropores to control intimal hyperplasia. J Artif Organs 2011; 14:348-356.
Related Publications (1)
Number Date Country
20170319338 A1 Nov 2017 US
Provisional Applications (1)
Number Date Country
61779891 Mar 2013 US
Divisions (1)
Number Date Country
Parent 14181965 Feb 2014 US
Child 15661549 US
Continuation in Parts (2)
Number Date Country
Parent 13485823 May 2012 US
Child 14181965 US
Parent 13078774 Apr 2011 US
Child 13485823 US